Please login to the form below

Not currently logged in
Email:
Password:

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Annalisa JenkinsUK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018 launch of the biomarker-based liquid biopsy system (LBS).

Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.

Jon Moynihan, chairman of PlaqueTec, said: “Dr Jenkins is a passionate and energetic leader with a proven track record of successfully translating exciting science from bench to bedside.

“We are pleased to welcome her to PlaqueTec at an important time for the company, as we will surely benefit from her extensive expertise in growing both private and public companies in the life sciences industry.”

Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at Bristol-Myers Squibb.

She said: “I look forward to working with the highly accomplished leadership team and board of directors at PlaqueTec to help advance the study and launch of its pioneering system through increased academic and biopharma collaborations.”

22nd November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics